No single medication has been proven to be the universally best treatment for vestibular migraine. The condition, which causes episodes of vertigo and dizziness tied to migraine biology, lacks the large-scale clinical trials that would let doctors rank one drug clearly above the rest. That said, a network meta-analysis pooling the available randomized trials found that valproic acid, propranolol, and venlafaxine were the only preventive drugs that beat placebo for reducing attack frequency, with valproic acid producing the largest effect. The real answer, though, depends heavily on your particular symptom pattern, other health conditions, and which side effects you can tolerate.
Why the Evidence Is So Thin
Vestibular migraine was not formally recognized with diagnostic criteria until 2012, when the Bárány Society and the International Headache Society published joint consensus criteria. Diagnosis still rests on a clinical history of recurrent vestibular episodes lasting between five minutes and 72 hours, a personal history of migraine, and a clear link between the vertigo and migraine-type symptoms like light sensitivity or headache, after other causes have been ruled out.1PubMed Central. Vestibular migraine: Diagnostic criteria Because the diagnosis is relatively new, drug companies and research groups have had less time and less funding to run the kind of large, rigorous trials that exist for ordinary migraine headache. Most of what doctors know about treating vestibular migraine is borrowed from migraine headache research or drawn from small, sometimes uncontrolled studies.
Triptans for Acute Attacks Are Surprisingly Disappointing
If you have garden-variety migraine headaches, triptans are often the go-to rescue drug. You might assume they work equally well for the vertigo side of vestibular migraine. They do not appear to. A Cochrane systematic review pooling the only two randomized trials of triptans for acute vestibular migraine attacks found that triptans “may result in little or no difference” in the proportion of people whose vertigo improved within two hours, and the certainty of the evidence was rated very low.2Cochrane Library. Interventions for the acute treatment of vestibular migraine
The larger of the two trials compared rizatriptan with placebo in 134 patients. About half of the rizatriptan-treated episodes saw vertigo drop from moderate or severe to mild or none at one hour, but so did about 56% of placebo-treated episodes. Most secondary measures were also negative, and rizatriptan caused more fatigue and sleepiness.3Brain. Vestibular migraine treatment: a comprehensive practical review An earlier small crossover trial with zolmitriptan enrolled only ten patients and could not produce meaningful results.4PubMed Central. Current Treatment Options in Vestibular Migraine In practice, some clinicians still try triptans for patients whose attacks include prominent headache, but there is no solid basis for expecting them to relieve the dizziness itself.
For the acute episode, most treatment remains symptomatic. Doctors often prescribe vestibular suppressants like meclizine or dimenhydrinate for short-term vertigo relief, sometimes combined with anti-nausea drugs. These are borrowed from motion sickness and general vertigo management and have not been tested in vestibular migraine trials specifically. The real therapeutic energy in this field is directed at prevention rather than acute rescue.
The Preventive Drugs with the Strongest Trial Evidence
A 2023 network meta-analysis pulled together all available randomized controlled trials comparing preventive treatments for vestibular migraine. Out of seven active treatments studied across seven trials, only three significantly outperformed placebo at reducing how often attacks occurred: valproic acid, propranolol, and venlafaxine. Of the three, valproic acid showed the largest reduction in attack frequency.5PubMed Central. Network Meta-analysis of Different Treatments for Vestibular Migraine Dropout rates were similar across treatments, suggesting that none of the three was dramatically worse to tolerate than placebo in the short term.
Propranolol, a beta-blocker, has been studied in several small trials. In one randomized study, patients on propranolol saw their average number of vertigo attacks fall from about 13 over four months down to roughly two, with Dizziness Handicap Inventory scores improving substantially.6PubMed. Propranolol and venlafaxine for vestibular migraine prophylaxis: A randomized controlled trial A separate observational study confirmed that propranolol reduced attack severity, frequency, and disability scores while improving quality of life.7PubMed Central. The Effectiveness of Medical Prophylactic Treatment on Vestibular Migraine and Its Effect on the Quality Of Life Propranolol is cheap, widely available, and familiar to most doctors, which makes it a common first-line choice in practice.
Venlafaxine, an antidepressant, performed comparably to propranolol in the same head-to-head trial, with both drugs producing similar drops in vertigo frequency and dizziness handicap scores.6PubMed. Propranolol and venlafaxine for vestibular migraine prophylaxis: A randomized controlled trial Venlafaxine’s dual role is appealing for certain patients, as discussed below.
Matching the Drug to Your Symptom Profile
One of the more useful developments in vestibular migraine treatment is the idea that the “best” drug depends on what your particular version of the condition looks like. A recent narrative review proposed phenotype-guided selection. Venlafaxine may be a better fit if you have coexisting anxiety or depression, if your dizziness gets worse in busy visual environments like supermarkets or scrolling screens, or if you overlap with a related condition called persistent postural-perceptual dizziness. Topiramate, on the other hand, may suit patients whose headaches are more prominent than their vertigo, or who have heightened sensitivity to light, sound, and motion.8PubMed Central. Phenotype-guided selection of venlafaxine and topiramate for vestibular migraine: a narrative review
Topiramate has some evidence behind it, though the trials are small. A randomized trial of 30 patients found that topiramate at 50 mg per day reduced both vertigo frequency and severity. Doubling the dose to 100 mg did not produce additional benefit and caused more patients to drop out because of side effects.9Research in Vestibular Science. Preventive medical treatment of vestibular migraine: a practical review A separate prospective study comparing topiramate with propranolol and cinnarizine found that all three reduced vertigo attacks, but topiramate was better at controlling headache frequency and severity.10The Egyptian Journal of Otolaryngology. Comparison between the effectiveness of three prophylactic drugs for vestibular migraine; cinnarizine, propranolol, and topiramate: prospective study
The practical takeaway is that you and your doctor should not just pick the statistically strongest drug from a meta-analysis. If anxiety is a major part of your picture, venlafaxine addresses two problems at once. If you have low blood pressure or asthma, propranolol may be a poor choice. If you are already overweight or have kidney stones, topiramate’s side effect profile could actually work in your favor since it tends to cause weight loss, or it could be a deal-breaker because of cognitive fogging. These individual factors matter more than small differences in trial averages.
Flunarizine and Other Calcium Channel Blockers
Flunarizine deserves its own mention because it is widely prescribed for vestibular migraine in Europe, Asia, and Latin America, though it is not available in the United States or Canada. An observational study found that roughly nine out of ten patients reported overall improvement with flunarizine, including reductions in both the duration and severity of vestibular episodes.11PubMed Central. Patient Experience of Flunarizine for Vestibular Migraine: Single Centre Observational Study A retrospective study comparing flunarizine with cinnarizine over eight months showed that baseline vertigo frequency dropped from about 1.6 episodes per month to 0.2, with an overall response rate above 80%. Flunarizine was slightly more effective than cinnarizine, and side effects were generally mild: sleepiness, some cognitive slowing, and weight gain.12PubMed. Flunarizine and cinnarizine in the prophylaxis of vestibular migraine and migraine-associated menière’s disease: An 8-month retrospective study
When compared head-to-head with propranolol and amitriptyline in a non-randomized controlled study, the three oral medications did not differ meaningfully in reducing attack frequency or improving disability scores.13PubMed Central. The effectiveness of propranolol, flunarizine, amitriptyline and botulinum toxin in vestibular migraine complaints and prophylaxis: a non-randomized controlled study So if you live in a country where flunarizine is available, it is a reasonable option, particularly if beta-blockers or antidepressants are off the table.
Verapamil, another calcium channel blocker, has been studied specifically in patients whose vestibular migraine overlaps with Ménière’s disease. Because that overlap syndrome can be tricky to treat, verapamil has been suggested as a first-line agent for those patients in particular.14Neurotherapeutics. Current Perspectives Advances in diagnosis and treatment of vestibular migraine and the vestibular disorders it mimics
Anti-CGRP Monoclonal Antibodies
The newer injectable drugs that target calcitonin gene-related peptide, a molecule heavily involved in migraine, are generating real excitement in the vestibular migraine world. These drugs (erenumab, fremanezumab, galcanezumab) are already approved for migraine headache prevention, and early data in vestibular migraine look promising.
A prospective observational study of 50 vestibular migraine patients treated with anti-CGRP antibodies reported that 90% achieved at least a 50% reduction in vertigo frequency after twelve months. Mean monthly days with dizziness dropped from about ten at baseline to less than one.15PubMed. Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study Another study found significant improvement in dizziness handicap scores and a notable reduction in abnormal eye-movement findings on vestibular testing after antibody therapy, in contrast to a lack of measurable improvement when the same patients had previously used conventional preventive drugs.16PubMed Central. Monoclonal Antibodies Targeting CGRP: A Novel Treatment in Vestibular Migraine A broader review of real-world evidence confirmed that most patients experienced at least a 50% drop in attacks, with minimal side effects like injection-site reactions and constipation.17São Paulo Medical Journal. Anti-CGRP monoclonal antibodies in the treatment of vestibular migraine: real-world evidence
These results are encouraging, but they come with caveats. The studies are observational, not randomized, and tend to be small. Patients in these cohorts had often failed multiple other preventive drugs, so they represent a harder-to-treat population, and the dramatic response rates might partly reflect regression to the mean or a placebo component that was not controlled for. Randomized trials are underway, and until those results come in, anti-CGRP antibodies are generally reserved for patients who have not responded to at least one or two oral preventive drugs. Cost is also a barrier: these monthly or quarterly injections run significantly more than generic oral medications.
Beyond Medication
Lifestyle modification is not a throwaway add-on for vestibular migraine. A study comparing nortriptyline (a tricyclic antidepressant) alone against nortriptyline combined with migraine-specific lifestyle changes found that the combination group had significantly larger reductions in dizziness and stress, and 94% reported improved quality of life compared with 88% in the medication-only group.18PubMed Central. Efficacy of Nortriptyline and Migraine Lifestyle Modifications in Vestibular Migraine Management Standard migraine lifestyle advice includes consistent sleep schedules, regular meals, adequate hydration, limiting caffeine and alcohol, and identifying personal dietary triggers.
Vestibular rehabilitation therapy, a structured exercise program that retrains the brain’s balance pathways, is commonly recommended alongside medication. A study of combined biofeedback and vestibular rehabilitation found that pairing the two produced better outcomes than either alone. The researchers proposed that biofeedback calms the autonomic nervous system, which in turn helps patients tolerate and benefit more from vestibular exercises.19PubMed Central. Combined biofeedback and vestibular rehabilitation therapy for vestibular migraine: clinical efficacy and neurobiochemical correlates Even if vestibular rehab does not eliminate attacks, it often helps patients feel less disabled between them by improving baseline balance and reducing motion sensitivity.
Noninvasive Vagus Nerve Stimulation
For people whose attacks resist both oral preventives and lifestyle changes, a handheld device that stimulates the vagus nerve through the skin of the neck has shown early promise. In a pilot study of 14 acute vestibular migraine attacks treated with noninvasive vagus nerve stimulation, 13 patients reported improvement in vertigo, with an average reduction of nearly 47% in vertigo intensity. All five patients who had headache alongside their vertigo also improved, with headache intensity dropping by about 63%.20PubMed. Acute vestibular migraine treatment with noninvasive vagus nerve stimulation This is a single, small, uncontrolled study, so it is far from definitive. But the device is already FDA-cleared for migraine and cluster headache, carries minimal side effects, and could fill a gap for patients who need acute relief but do not get it from triptans.
How the Brain Ties Vertigo to Migraine
Understanding why so many different drug classes can help vestibular migraine starts with the underlying biology. The brainstem’s balance-processing centers have dense two-way connections with the same pain-modulating structures involved in migraine headache, including the locus coeruleus and the raphe nuclei.21PubMed Central. New insights into pathophysiology of vestibular migraine These shared circuits mean that the neurochemical disruption behind a migraine can spill over into the vestibular system, producing vertigo and motion sensitivity even without headache. It also means that drugs targeting serotonin, norepinephrine, calcium channels, CGRP, or GABA all have plausible routes into the problem. The flip side of this biological richness is that no single pathway dominates for every patient, which is exactly why there is no one-size-fits-all answer. The medication that silences the circuit in your brain may do little for someone whose attacks travel a slightly different neurochemical path.